PMA device
Synvisc-One
Sanofi Genzyme Corp. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Feb 26, 2009, newest Feb 26, 2009Knee osteoarthritis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
37
Naming "Synvisc-One"
MAUDE reports
2,102
Brand "Synvisc-One", since 2015
PubMed studies
23
Mentioning "Synvisc-One"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Synvisc-One
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- SYNVISC-ONEPMA supplement
P940015-S012 · Decided Feb 26, 2009 · 618 days after receipt · Panel Track
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Synvisc-One", any status and sponsor, newest update first.
- Genicular Nerve Radiofrequency Ablation Versus Hyaluronic Acid Injection for Knee Osteoarthritis PainNot yet recruiting
Hospital Universitari Joan XXIII de Tarragona.Academic, hospital or other
NCT07901374 · 70 participants (planned) · Start Nov 2026 · Primary completion May 2028
Device: Intra-articular Hyaluronic Acid · For: Knee Osteoarthritis; Chronic Knee Pain
Sites: Tarragona, Spain
- Verifying the Effectiveness of the NUsurface® SystemPivotal-lookingCompleted
Phoenix KineticsNot on our public-company list
NCT02108496 · 337 participants · Start Jul 2014 · Primary completion Jun 2021
Device: NUsurface® Meniscus Implant · For: Meniscectomy; Osteoarthritis
Sites: Indianapolis, Indiana; Boston, Massachusetts; Roxbury Crossing, Massachusetts · 9 sites in all
- Comparative Effectiveness and Safety of Two Hyaluronic Acid Products in Knee OsteoarthritisNot yet recruiting
Coordinación de Investigación en Salud, MexicoGovernment (non-federal)
NCT07911696 · 160 participants (planned) · Start Nov 2026 · Primary completion Jun 2027
Device: Hylan G-F 20; Cross-Linked Sodium Hyaluronate · For: Osteoarthritis, Knee
Sites: Mexico City, Mexico
34 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Synvisc-One", and for the whole product code for context.
This brand
2,102 reports: 520 malfunction, 1,530 injury, 34 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
MW6004418 · Received Oct 22, 2026 · Event dated Aug 14, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Material Integrity Problem
Patient problem as coded: Loss of Range of Motion
- Synvisc OneOther
MW6004253 · Received Oct 20, 2026 · Event dated Sep 14, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Use of Device Problem; Mechanical Jam
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Synvisc OneOther
MW6003703 · Received Oct 8, 2026 · Event dated Sep 30, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Break; Detachment of Device or Device Component
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0607-2018 · Started Dec 11, 2017
Reason given: Contamination with Methylbacterium thiocyanatum
Cause as FDA categorized it: Environmental control · Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Published research
The most relevant PubMed records for "Synvisc-One"[tiab]. The summary above synthesizes these.
- Twelve-month efficacy of carboxymethyl-chitosan in refractory knee osteoarthritis: A randomized controlled trial (PIONEER).
Van Overschelde P, Vansintjan P, Portelange N, et al. · Osteoarthr Cartil Open · 2025Clinical Trial
- Methylobacterium infection of an arthritic knee.
Beck ET, Bateman AC, Maccoux D · JMM Case Rep · 2019Case Reports
- Non-Inferiority of a Single Injection of Sodium Hyaluronate Plus Sorbitol to Hylan G-F20: A 6-Month Randomized Controlled Trial.
Cortet B, Lombion S, Naissant B, et al. · Adv Ther · 2021Multicenter Study, Randomized Controlled Trial
- Characterization of the visco-elastic properties of hyaluronic acid.
Lázaro B, Alonso P, Rodriguez A, et al. · Biorheology · 2018Comparative Study
- A Comprehensive Review of Viscosupplementation in Osteoarthritis of the Knee.
Peck J, Slovek A, Miro P, et al. · Orthop Rev (Pavia) · 2021Review
- Nanoparticle Lubricant and Imaging Agent: Preventing and Assessing Cartilage Tissue Damage.
Lawson TB, Joenathan A, DeMoya CD, et al. · ACS Appl Mater Interfaces · 2025
- A single intra-articular injection of JTA-004, a combination of human plasma, hyaluronic acid, and clonidine, versus placebo in symptomatic knee osteoarthritis: A Phase 3 trial.
Bihlet AR, Henrotin Y, Lau EMC, et al. · Osteoarthritis Cartilage · 2026Clinical Trial, Phase III, Randomized Controlled Trial
- Immunological response to bolus versus multiple injections of hylan G-F 20 (Synvisc) in a murine biocompatibility model.
Markel DC, Jackson NM, Esquivel AO, et al. · J Biomed Mater Res B Appl Biomater · 2014
- A synthetic polymeric biolubricant imparts chondroprotection in a rat meniscal tear model.
Wathier M, Lakin BA, Cooper BG, et al. · Biomaterials · 2018Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid.
Nicholls M, Manjoo A, Shaw P, et al. · Adv Ther · 2018Research Support, Non-U.S. Gov't
- Improvement in condition specific and generic quality of life outcomes in patients with knee osteoarthritis following single intraarticular viscosupplementation injection.
Acharya K, Si V, Madi S · J Clin Orthop Trauma · 2022
- Comparison of Single Intra-Articular Injection of Novel Hyaluronan (HYA-JOINT Plus) with Synvisc-One for Knee Osteoarthritis: A Randomized, Controlled, Double-Blind Trial of Efficacy and Safety.
Sun SF, Hsu CW, Lin HS, et al. · J Bone Joint Surg Am · 2017Comparative Study, Randomized Controlled Trial
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.